熱門資訊> 正文
Candel暂停了CAN-2409在前列腺癌类型中的开发
2025-11-15 00:47
- Candel Therapeutics (CADL) said it is pausing the development of CAN-2409 specifically for an indication in borderline resectable pancreatic adenocarcinoma, where it is in phase 2 testing.
- The company said that it wants to focus the asset in localized, intermediate/high risk pancreatic cancer and non-small lung cancer. Developed on an adenovirus platform, CAN-2409 is ready for a BLA submission in the former indication and in phase 2 for the latter.
- Candel noted a phase 3 study in NSCLC is slated to begin in Q2 2026.
- The biopharma's Q3 financial results, released on Thursday, missed on the bottom line.
More on Candel Therapeutics
- Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now
- Candel Therapeutics: Potentially The Next Exciting Oncology Story
- Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors
- Candel Therapeutics signs $130M term loan facility with Trinity Capital
- Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
推薦文章
資金覆盤 | 北水迴流抄底！淨買入港股超128億港元，搶籌阿里、騰訊、中芯國際
「大空頭」清倉，巴菲特瘋狂囤積現金！當前美股泡沫有多少？
一周財經日曆 | 下周必看！全球股王英偉達將揭曉財報，小鵬、小米、拼多多也輪番登場
新股暗盤 | "新能源材料龍頭"中偉新材跌約1.5%，預計該股將於11月17日正式掛牌上市
全文|B站Q3業績會實錄：B站有國內最好的AI創作者及用户
華盛早報 | 美聯儲放鷹，美股全線大跌！騰訊、京東財報超預期，B站扭虧為盈
美股機會日報 | 阿里巴巴擬改版「千問」對標ChatGPT！思科盤前大漲7%，業績超預期並上調指引
「木頭姐」買入逾2500萬美元阿里巴巴股票，繼續減持特斯拉
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
